Evidence map›Paper›PMID 38462610›Full record

ArticleBMC health services research2024

The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology.

Christine L Paul, Nicole M Verrills, Stephen Ackland, Rodney Scott, Susan Goode, Ann Thomas, Sarah Lukeman, Sarah Nielsen, Judith Weidenhofer, James Lynam and 9 more

Abstract read
In one paragraph

Article in BMC health services research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Christine L PaulSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia. Christine.paul@newcastle.edu.au.
Nicole M VerrillsHunter Medical Research Institute, Newcastle, NSW, Australia.
Stephen AcklandSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Rodney ScottHunter Medical Research Institute, Newcastle, NSW, Australia.
Susan GoodeSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Ann ThomasSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Sarah LukemanSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Sarah NielsenSchool of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, NSW, Australia.
Judith WeidenhoferHunter Medical Research Institute, Newcastle, NSW, Australia.
James LynamSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Elizabeth A FradgleySchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Jarad MartinCalvary Mater Hospital Newcastle, Newcastle, NSW, Australia.
Peter GreerCalvary Mater Hospital Newcastle, Newcastle, NSW, Australia.
Stephen SmithSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Cassandra GriffinSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Kelly A Avery-KiejdaHunter Medical Research Institute, Newcastle, NSW, Australia.
Nick ZdenkowskiSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Andrew SearlesSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.
Shanthi RamanathanSchool of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTranslating research, achieving impact, and assessing impact are important aspirations for all research collaboratives but can prove challenging. The Hunter Cancer Research Alliance (HCRA) was funded from 2014 to 2021 to enhance capacity and productivity in cancer research in a regional centre in Australia. This study aimed to assess the impact and benefit of the HCRA to help inform future research investments of this type.

methodThe Framework to Assess the Impact from Translational health research (FAIT) was selected as the preferred methodology. FAIT incorporates three validated methodologies for assessing impact: 1) Modified Payback; 2) Economic Analysis; and 3) Narrative overview and case studies. All three FAIT methods are underpinned by a Program Logic Model. Data were collected from HCRA and the University of Newcastle administrative records, directly from HCRA members, and website searches.

resultsIn addition to advancing knowledge and providing capacity building support to members via grants, fellowships, scholarships, training, events and targeted translation support, key impacts of HCRA-member research teams included: (i) the establishment of a regional biobank that has distributed over 13,600 samples and became largely self-sustaining; (ii) conservatively leveraging $43.8 M (s.a.$20.5 M - $160.5 M) in funding and support from the initial $9.7 M investment; (iii) contributing to clinical practice guidelines and securing a patent for identification of stem cells for endometrial cell regeneration; (iv) shifting the treatment paradigm for all tumour types that rely on nerve cell innervation, (v) development and implementation of the world's first real-time patient treatment verification system (Watchdog); (vi) inventing the effective 'EAT' psychological intervention to improve nutrition and outcomes in people experiencing radiotherapy for head and neck cancer; (vi) developing effective interventions to reduce smoking rates among priority groups, currently being rolled out to disadvantaged populations in NSW; and (vii) establishing a Consumer Advisory Panel and Consumer Engagement Committee to increase consumer involvement in research.

conclusionUsing FAIT methodology, we have demonstrated the significant impact and downstream benefits that can be achieved by the provision of infrastructure-type funding to regional and rural research collaboratives to help address inequities in research activity and health outcomes and demonstrates a positive return on investment.

Indexed as

NeoplasmsTranslational Research, BiomedicalAustraliaHumansProgram EvaluationTranslational Science, BiomedicalCancer researchConsumer involvementImpact assessmentRural and regional healthTranslational research

Identifiers

PMID38462610
PMCPMC10926601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.